No meaningful difference was found in either injectable or implant birth control when compared to an IUD.
June 6, 2019: HIV/STI risk perceptions differ by race; psychosocial issues and HIV risk among young trans women; switching to dolutegravir/atazanavir; reports of severe hepatotoxicity on dolutegravir.
May 30, 2019: Myocardial infarction risk among people with HIV; dolutegravir vs. efavirenz; a new way to estimate date of seroconversion; identifying people at imminent risk for disengagement from care.
Our HIV research agenda has to address the world outside of a clinical trial, vaccine researcher Stephaun E. Wallace, Ph.D., argues.
May 16, 2019: The dwindling value of baseline genotype testing; severe insomnia and cardiovascular disease; cardiovascular risk stratified by sex among people over 50; the persistence of racial disparities among women diagnosed with HIV.
"For us who focus on HIV prevention research, it is paramount that we go where the epidemic is in this country," said Michele Andrasik, Ph.D.
Two models, one from Washington State and another from Los Angeles County, can be duplicated elsewhere to get people into care, experts say.
April 25, 2019: stigma and viral load among African-American women; U.S. HIV incidence sans racial disparities; the care continuum is failing young MSM; a moment of reckoning regarding HIV among U.S. youth.
A new study demonstrates the phenomenon, but experts say more research needs to determine why it occurs -- and what researchers can do differently to reduce it.
April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.